Science Daily17h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Hosted on MSN4d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Daily8h
Dapagliflozin prevents renal injury by improving mitochondrial function and reducing oxidative stress in diabetes patients: Study
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
FiercePharma12d
Nephrologists already aboard GLP-1 bandwagon, providing launchpad for Ozempic in CKD: Spherix
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Pulse21h
Sponsored CPD: Key questions on current drug treatment options in type 2 diabetes
Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Armed robbery in Revesby5h
First-Ever Drug Cuts Heart Attacks, Strokes in Diabetes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
‘First of its kind’ medication can significantly reduce heart attacks and strokes
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Healio21h
Few hospitalized adults with type 2 diabetes prescribed SGLT2, GLP-1 medication
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
Daily12d
SGLT2 Inhibitors versus DPP4 Inhibitors: Lower Nephrolithiasis Risk Found in Diabetes Patients, Study Finds
The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...
MedPage Today5d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
"The benefits seen here are distinct from those seen with the other very popular SGLT2 inhibitors in widespread clinical use for diabetes, heart failure, and kidney disease." "Few people had ...